Genmab books higher royalties

Royalties from the CD38-targeted antibody therapeutic Darzalex (daratumumab) were the main source of revenue for Genmab A/S in the 2017 first quarter. Developed by Genmab and licensed to Janssen Biotech Inc, the product is approved for the treatment of multiple myeloma.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Denmark